NEW YORK--(BUSINESS WIRE)--The Channel Group, LLC announced today that Vijay Aggarwal, Ph.D. has joined
The Channel Group and its affiliate, BioMed Transition Partners, as a Partner. Dr. Aggarwal has over thirty years of
experience in both pharmaceutical services and clinical diagnostics. Most recently, Dr. Aggarwal was President and
CEO of Aureon Laboratories, Inc., a predictive pathology company offering advanced tissue analysis services to
practicing physicians and the pharmaceutical industry. Previously, he was President of AAI Development Services,
Inc., a contract research and development services company serving the pharmaceutical and biotech industries. Prior
to holding that position, Dr. Aggarwal was President of Quest Diagnostic Ventures, where he had responsibility for
new technology, new business models, clinical trials testing, and direct–to-consumer strategies. Earlier in his career,
Dr. Aggarwal held many positions with SmithKline Beecham Clinical Laboratories (“SBCL”), the clinical laboratory
operations of SmithKline Beecham plc, including direct responsibility for all of SBCL’s U.S.-based laboratories as
Executive Vice President of Laboratories, Vice President of Managed Care. Dr. Aggarwal currently serves on the
boards of several privately held diagnostic testing companies, including: Aureon Laboratories; Targeted Diagnostics
and Therapeutics, Inc.; Prognostix, Inc.; and, Viracor-IBT Laboratories. He earned a Ph.D. in Pharmacology from the
Medical College of Virginia.
“Vijay’s scientific training in pharmacology and his significant knowledge and corporate management experience in the clinical diagnostic industry expands our existing expertise and adds another dimension to our team,” commented Allan R. Goldberg, Ph.D., a Managing Partner of The Channel Group.
“The Channel Group and its affiliate, BioMed Transition Partners, have been built by accomplished operating executives who have solid track records in the biotechnology/biomedical industries. Together we anticipate creating several exciting new companies and helping other companies achieve their potential,” said Vijay Aggarwal.
About The Channel Group
The Channel Group is a New York-based venture investment, development, and management company that focuses on the creation of companies in the life sciences and biomedical industries. Its Managing Partners include Robert J. Beckman and Philip N. Sussman, in addition to Dr. Goldberg. See www.thechannelgroup.com for further information.
BioMed Transition Partners
BioMed Transition Partners provides advisory and turn-around management support to biomedical companies that are under-performing or in transition. See www.biomedtransitionpartners.com for further information.
“Vijay’s scientific training in pharmacology and his significant knowledge and corporate management experience in the clinical diagnostic industry expands our existing expertise and adds another dimension to our team,” commented Allan R. Goldberg, Ph.D., a Managing Partner of The Channel Group.
“The Channel Group and its affiliate, BioMed Transition Partners, have been built by accomplished operating executives who have solid track records in the biotechnology/biomedical industries. Together we anticipate creating several exciting new companies and helping other companies achieve their potential,” said Vijay Aggarwal.
About The Channel Group
The Channel Group is a New York-based venture investment, development, and management company that focuses on the creation of companies in the life sciences and biomedical industries. Its Managing Partners include Robert J. Beckman and Philip N. Sussman, in addition to Dr. Goldberg. See www.thechannelgroup.com for further information.
BioMed Transition Partners
BioMed Transition Partners provides advisory and turn-around management support to biomedical companies that are under-performing or in transition. See www.biomedtransitionpartners.com for further information.
